pSivida Corp

PRODUCTS / Retisert®

Posterior Uveitis / Retisert®

Posterior uveitis is characterized by inflammation of the lining of the back of the eye. While it affects fewer than 200,000 people in the U.S., this serious and difficult to treat disease is the third largest cause of vision loss.

Retisert (fluocinolone acetonide intravitreal implant) is the world's first approved intravitreal drug implant for the treatment of chronic non-infectious posterior uveitis, a sight-threatening inflammatory disease affecting the posterior segment of the eye. Retisert was approved as an orphan drug by the U.S. FDA in April 2005 and is marketed under license by Bausch & Lomb.

Retisert is a very small device, about the size of a grain of rice, which contains the corticosteroid fluocinolone acetonide (FA). Retisert is surgically implanted in the eye through a small, 3-4 mm incision and releases precise amounts of medication each day for approximately 2.5 years.

Uveitis is one of the leading causes of blindness for middle-aged people in the Western world. It is estimated to cause 10% to 15% of all cases of total blindness in the United States. Nearly half the people with posterior uveitis develop visual impairment or legal blindness.

Currently, Retisert is the only long-acting product approved by the FDA for the treatment of non-infectious Uveitis.


Links to additional information:

Additional information on Retisert, including important product safety information »

pSivida